Figure 1From: A 6-week, multicentre, randomised, double-blind, double-dummy, active-controlled, clinical safety study of lumiracoxib and rofecoxib in osteoarthritis patients Patient flow diagram. †Patients with multiple occurrences of a major protocol violation (PV) were counted only once in that category of PV.Back to article page